Comparison of prognostic ability of EndoPredict^® Breast Cancer Prognostic
Test and Oncotype DX^®

Decisions on the use of adjuvant chemotherapy in ER positive, HER2 negative primary breast cancer are guided by the risk of distant recurrence. EndoPredict provides prognostic information from a molecular signature combined with tumor size and nodal status (EPclin Risk Score). Oncotype DX^® provides prognostic information only from a molecular signature (Recurrence Score – RS).

This study validated the prognostic value of EndoPredict and compared the prognostic ability of EndoPredict with Oncotype DX^®.

Click the button to download your free copy of the comparison clinical summary and learn more about this key study.